NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128 ·Status: COMPLETED ·Phase: PHASE1

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

NCT06888492 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05859776 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Safety and Tolerability of Oral CM082 in Patients With wAMD

NCT03710863 ·Status: UNKNOWN ·Phase: PHASE2

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

NCT04857177 ·Status: COMPLETED ·Phase: PHASE3

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT00473928 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)

NCT04468997 ·Status: UNKNOWN ·Phase: PHASE1

X-82 to Treat Age-related Macular Degeneration

NCT02348359 ·Status: TERMINATED ·Phase: PHASE2

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

NCT00346957 ·Status: COMPLETED ·Phase: PHASE2

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

NCT02599064 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT03295877 ·Status: COMPLETED ·Phase: PHASE1

A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD

NCT01013376 ·Status: COMPLETED ·Phase: PHASE1

Phase 1 Study of CM082 in Patients With wAMD

NCT02452385 ·Status: SUSPENDED ·Phase: PHASE1

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

NCT04964089 ·Status: COMPLETED ·Phase: PHASE3

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07029945 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

NCT06737354 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1

Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

NCT01310686 ·Status: UNKNOWN

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

NCT06743646 ·Status: RECRUITING ·Phase: PHASE3

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852 ·Status: TERMINATED ·Phase: PHASE1

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

NCT00447954 ·Status: COMPLETED ·Phase: PHASE2

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

NCT03675880 ·Status: UNKNOWN ·Phase: PHASE1

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

NCT07158775 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

NCT02461771 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

NCT00383370 ·Status: COMPLETED ·Phase: PHASE1